Key result
Empagliflozin reduced the composite primary endpoint of cardiovascular death and hospitalization for heart failure by 25% compared with placebo.
RCT (n=3,730)
Double-blind
Randomized
Hazard Ratio: 0.75 (95% CI 0.65–0.86)
p-value: p=<0.001
This editorial summarizes key updates from the virtual ESC Congress 2020, highlighting pivotal clinical trials and new guidelines across various cardiology subspecialties.
The 2020 annual Congress of the European Society of Cardiology (ESC) was the first ever to be held virtually. Under the spotlight of 'the cutting edge of cardiology', exciting and ground-breaking cardiovascular (CV) science was presented both in basic and clinical research. This commentary summarizes essential updates from ESC 2020-The Digital Experience. Despite the challenges that coronavirus disease 2019 (COVID-19) has posed on the conduct of clinical trials, the ESC Congress launched the results of major studies bringing innovation to the field of general cardiology, cardiac surgery, heart failure, interventional cardiology, and atrial fibrillation. In addition to three new ESC guidelines updates, the first ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease were presented. As former ESC president, Professor Casadei undoubtedly pointed out the ESC Congress 2020 was a great success. During the ESC 2020 Congress, BMC Cardiovascular Disorders updated to seven journal sections including Arrhythmias and Electrophysiology, CV Surgery, Coronary Artery Disease, Epidemiology and Digital health, Hypertension and Vascular biology, Primary prevention and CV Risk, and Structural Diseases, Heart Failure, and Congenital Disorders. To conclude, an important take-home message for all CV health care professionals engaged in the COVID-19 pandemic is that we must foresee and be prepared to tackle the dramatic, long-term CV complications of COVID-19 patients.
No takes yet. Share an insight, caveat, or question.
Gallego-Colón et al. (2020) conducted an RCT in Chronic Heart Failure (n=3,730). Empagliflozin vs. Placebo was evaluated on Composite of CV death and HHF (HR 0.75, 95% CI 0.65-0.86, p=<0.001). Empagliflozin reduced the composite primary endpoint of cardiovascular death and hospitalization for heart failure by 25% compared with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: